- Home
- HRTX vs MBX Comparison
HRTX vs MBX Comparison
Compare HRTX & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- MBX
- Stock Information
- Founded
- HRTX 1983
- MBX 2018
- Country
- HRTX United States
- MBX United States
- Employees
- HRTX N/A
- MBX N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- MBX
- Sector
- HRTX Health Care
- MBX
- Exchange
- HRTX Nasdaq
- MBX NYSE
- Market Cap
- HRTX 350.4M
- MBX 300.5M
- IPO Year
- HRTX 1987
- MBX 2024
- Fundamental
- Price
- HRTX $2.11
- MBX $11.11
- Analyst Decision
- HRTX Strong Buy
- MBX Strong Buy
- Analyst Count
- HRTX 2
- MBX 5
- Target Price
- HRTX $5.50
- MBX $37.40
- AVG Volume (30 Days)
- HRTX 1.8M
- MBX 333.6K
- Earning Date
- HRTX 05-06-2025
- MBX 05-16-2025
- Dividend Yield
- HRTX N/A
- MBX N/A
- EPS Growth
- HRTX N/A
- MBX N/A
- EPS
- HRTX N/A
- MBX N/A
- Revenue
- HRTX $148,518,000.00
- MBX N/A
- Revenue This Year
- HRTX $11.18
- MBX N/A
- Revenue Next Year
- HRTX $13.15
- MBX N/A
- P/E Ratio
- HRTX N/A
- MBX N/A
- Revenue Growth
- HRTX 12.43
- MBX N/A
- 52 Week Low
- HRTX $1.04
- MBX $4.81
- 52 Week High
- HRTX $3.93
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- HRTX 47.04
- MBX N/A
- Support Level
- HRTX $2.00
- MBX N/A
- Resistance Level
- HRTX $2.61
- MBX N/A
- Average True Range (ATR)
- HRTX 0.18
- MBX 0.00
- MACD
- HRTX -0.01
- MBX 0.00
- Stochastic Oscillator
- HRTX 20.63
- MBX 0.00
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.